Our goal is to develop a portfolio of less harmful alternatives to continued cigarette smoking. For these reduced-risk products*, we’ve implemented a comprehensive and rigorous product-development and assessment approach. We were inspired by the methods used in the pharmaceutical industry and aligned with U.S. FDA Food and Drug Administration draft guidance for Modified Risk Tobacco Product (MRTP)1 applications, Good Laboratory Practices (GLPs), and Good Clinical Practices (GCPs). The assessment methods cover product-design controls, a range of toxicological tests (including limited animal testing), clinical studies, pre-market consumer perception and behavior studies, and post-market assessments.
Sharing and gathering feedback on our research helps answer the questions raised by regulators, scientific experts, and society at large. We share our methodologies and findings through scientific publications, presentations at scientific conferences, and on PMIScience.com. Since 2011, we’ve published over 200 articles and book chapters in peer-reviewed scientific journals. We register all our clinical studies with ClinicalTrials.gov. We’ve also recently published our first Scientific Update – a summary of the latest research and developments relating to our reduced-risk products.
We recognize that our scientific work must also be assessed by independent experts. We welcome such review and are committed to share scientific data for independent verification by qualified third parties. We use an online platform called sbvIMPROVER.com to encourage verification by independent scientists of our methods and results. And we’ve recently launched an investigator-initiated-study program to encourage third parties to conduct studies with our reduced-risk products.
1 Food and Drug Administration (2012) Modified Risk Tobacco Product Applications. Vol. 77 FR 20026, Federal Register.
Discover our compliance and integrity program and explore our Guidebook for Success.
Children shouldn't smoke or use products containing nicotine.